Anlotinib is currently being evaluated in numerous clinical trials spanning Phase 1 safety evaluations to Phase 4 post-marketing research across oncology indications, including non-small cell lung cancer, soft tissue sarcoma, esophageal squamous cell carcinoma, breast cancer, and pheochromocytoma or paraganglioma. Conducted by diverse organizations, including academic medical centers and pharmaceutical sponsors, these studies evaluate both monotherapies and combination regimens. The trial landscape represents the full spectrum of recruitment statuses, encompassing studies that are not yet recruiting, actively recruiting, active but not recruiting, and completed.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07540390 | NOT_YET_RECRUITING | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2026-05-08 | PHASE3 |
| NCT07612098 | NOT_YET_RECRUITING | Soft Tissue Sarcoma (STS) |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2026-07-01 | PHASE2 |
| NCT06992336 | RECRUITING | Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2025-04-10 | PHASE2 |
| NCT07156643 | NOT_YET_RECRUITING | Locally Advanced Soft Tissue Sarcoma |
The First Affiliated Hospital with Nanjing Medical University |
2025-10-01 | PHASE2 |
| NCT07520760 | RECRUITING | HER 2 Negative Breast Cancer |
Sun Yat-sen University |
2026-04-01 | PHASE2 |
| NCT07193186 | NOT_YET_RECRUITING | Thyroid Cancer |
Fudan University |
2026-04-01 | PHASE2 |
| NCT06662877 | NOT_YET_RECRUITING | Biliary Tract Cancer; Second Line Treatment; Chemotherapy; Tyrosine Kinase Inhibitor |
Sun Yat-sen University |
2024-11-25 | PHASE2; PHASE3 |
| NCT07562581 | RECRUITING | Non-small Cell Lung Caner; KRAS-mutated; Metastasis; Previous Treamted |
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. |
2026-06-15 | PHASE2 |
| NCT07643350 | NOT_YET_RECRUITING | NSCLC |
The Third Xiangya Hospital of Central South University |
2026-05-15 | PHASE2 |
| NCT07470840 | NOT_YET_RECRUITING | Locally Advanced or Metastatic Renal Cell Carcinoma |
Fujian Cancer Hospital |
2027-02-01 | PHASE2 |
| NCT07355855 | NOT_YET_RECRUITING | Rhabdomyosarcoma |
Fudan University |
2026-01 | PHASE2 |
| NCT07627464 | NOT_YET_RECRUITING | Renal Cell Carcinoma (RCC) |
Tianjin Medical University Cancer Institute and Hospital |
2026-05-31 | PHASE2 |
| NCT07239622 | NOT_YET_RECRUITING | Ovarian Cancer; Ovarian Clear Cell Carcinoma |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2026-01-01 | PHASE2 |
| NCT07646080 | NOT_YET_RECRUITING | Dermatofibrosarcoma Protuberans (DFSP) |
Yanjie Zhang, MD |
2026-06-15 | PHASE2 |
| NCT07075250 | NOT_YET_RECRUITING | Platinum-resistant Ovarian Cancer (PROC) |
Peking University People's Hospital |
2025-09-01 | PHASE4 |
| NCT07671560 | NOT_YET_RECRUITING | ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib |
Qiming Wang |
2026-07-01 | PHASE4 |
| NCT07636226 | NOT_YET_RECRUITING | Small Cell Lung Cancer |
Sun Yat-sen University |
2026-07-30 | PHASE2; PHASE3 |
| NCT07128693 | NOT_YET_RECRUITING | Esophageal Squamous Cell Carcinoma |
The First Affiliated Hospital of Zhengzhou University |
2025-09 | PHASE2 |
| NCT07446335 | NOT_YET_RECRUITING | Advanced Esophageal Squamous Cell Carcinoma |
The First Affiliated Hospital of Zhengzhou University |
2026-04 | PHASE3 |
| NCT07137884 | NOT_YET_RECRUITING | Rhabdomyosarcoma Recurrent; Maintenance Treatment |
Sun Yat-sen University |
2025-10-01 | PHASE2 |
| NCT07294261 | NOT_YET_RECRUITING | Local Advanced or Metastatic NSCLC |
Sun Yat-sen University |
2025-12-23 | PHASE2 |
| NCT07780578 | NOT_YET_RECRUITING | Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line |
Fudan University |
2026-09-30 | PHASE2 |
| NCT06356675 | NOT_YET_RECRUITING | Advanced NSCLC |
The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine |
2024-07-01 | PHASE4 |
| NCT07396454 | RECRUITING | HER2-Negative Breast Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2026-02-10 | PHASE2 |
| NCT07616141 | NOT_YET_RECRUITING | Adenoid Cystic Carcinoma |
Eye & ENT Hospital of Fudan University |
2026-06-01 | PHASE2 |
| NCT07632209 | NOT_YET_RECRUITING | SCLC, Extensive Stage |
Yayi He |
2026-06 | PHASE2 |
| NCT07165951 | RECRUITING | Metastatic Pancreatic Ductal Adenocarcinoma |
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. |
2025-12-02 | PHASE3 |
| NCT07455019 | RECRUITING | Esophageal Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2025-05-01 | PHASE2 |
| NCT04322617 | RECRUITING | Non-small Cell Lung Cancer |
Hunan Province Tumor Hospital |
2020-03-24 | PHASE2; PHASE3 |
| NCT07363512 | NOT_YET_RECRUITING | HCC - Hepatocellular Carcinoma |
Henan Cancer Hospital |
2026-01-05 | PHASE2 |
| NCT07545213 | NOT_YET_RECRUITING | Non-small Cell Lung Cancer; EGFR Mutant Advanced Non-small Cell Lung Cancer |
The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
2026-04-20 | PHASE2 |
| NCT07537777 | NOT_YET_RECRUITING | Hepatocellular Carcinoma (HCC); First-line Targeted Therapy Failure; Oligometastatic Hepatocellular Carcinoma; Benmelstobart; Anlotinib; SBRT |
Nanfang Hospital, Southern Medical University |
2026-04-20 | PHASE2 |
| NCT07385079 | NOT_YET_RECRUITING | Nasopharyngeal Cancinoma (NPC); Nasopharyngeal Cancer |
Sun Yat-sen University |
2026-03-01 | PHASE3 |
| NCT06848439 | NOT_YET_RECRUITING | Mouth Neoplasms; Neoadjuvant Therapy; Immunotherapy; Molecular Targeted Therapy |
Jiangsu Cancer Institute & Hospital |
2025-06-15 | PHASE2 |
| NCT07602101 | NOT_YET_RECRUITING | Clear Cell Renal Cell Carcinoma |
RenJi Hospital |
2026-05-31 | PHASE2 |
| NCT06681285 | NOT_YET_RECRUITING | Esophageal Carcinoma |
Hebei Medical University Fourth Hospital |
2024-11-01 | PHASE2 |
| NCT07010393 | NOT_YET_RECRUITING | Thyroid Neoplasms |
Fujian Medical University |
2025-07-01 | PHASE4 |
| NCT04165330 | ACTIVE_NOT_RECRUITING | Solid Tumor, Adult; Soft Tissue Sarcoma; Non Small Cell Lung Cancer; Small Cell Lung Cancer |
Sarcoma Oncology Research Center, LLC |
2019-10-17 | PHASE1; PHASE2 |
| NCT07398326 | RECRUITING | Colorectal Cancer |
Shanghai Changzheng Hospital |
2026-02-24 | PHASE2 |
| NCT07205185 | NOT_YET_RECRUITING | Soft Tissue Sarcoma (STS) |
Fudan University |
2025-10-01 | PHASE2 |
| NCT05167994 | RECRUITING | Sarcoma,Soft Tissue; Extremity; Trunk; Anlotinib; Intensity-modulated Radiotherapy; Major Wound Complications |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2020-05-01 | PHASE2 |
| NCT05582499 | RECRUITING | Breast Neoplasm; Breast Cancer; Breast Tumors; Triple-Negative Breast Cancer (TNBC); HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer |
Fudan University |
2022-11-01 | PHASE2 |
| NCT07581821 | RECRUITING | Recurrent or Metastatic Nasopharyngeal Carcinoma |
Ming-Yuan Chen |
2025-09-15 | PHASE2 |
| NCT07728955 | NOT_YET_RECRUITING | Small Cell Lung Cancer ( SCLC ) |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2026-08-01 | PHASE3 |
| NCT07627347 | RECRUITING | ESCC |
Nanfang Hospital, Southern Medical University |
2026-05-18 | |
| NCT06141226 | RECRUITING | Non-small-cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2023-04-12 | PHASE2 |
| NCT07745257 | NOT_YET_RECRUITING | HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases |
Sun Yat-sen University |
2026-08-28 | PHASE2 |
| NCT07444918 | NOT_YET_RECRUITING | Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma) |
Tianjin Medical University Cancer Institute and Hospital |
2026-03-01 | PHASE2 |
| NCT07307443 | NOT_YET_RECRUITING | SMARCA4-Deficient Tumor; Locally Advanced or Metastatic Lung Cancer |
Zhijie Wang |
2026-02-01 | PHASE2 |
| NCT06475599 | NOT_YET_RECRUITING | Endometrial Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2024-07 | PHASE3 |
| NCT06662006 | RECRUITING | Advanced Metastatic Pancreatic Cancer |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2024-03-01 | PHASE2 |
| NCT07172412 | NOT_YET_RECRUITING | Extensive Stage Lung Small Cell Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2025-11 | PHASE2 |
| NCT03016819 | RECRUITING | Alveolar Soft Part Sarcoma; Leiomyosarcoma; Synovial Sarcoma; Soft-Tissue Sarcoma |
Advenchen Laboratories, LLC |
2017-08-15 | PHASE3 |
| NCT07231575 | NOT_YET_RECRUITING | Neoadjuvant Immunotherapy; NSCLC; Chemo-free Therapy |
Sun Yat-sen University |
2025-11-10 | PHASE2 |
| NCT07330544 | RECRUITING | Breast Cancer |
Zhejiang Cancer Hospital |
2025-11-24 | PHASE2 |
| NCT06978153 | NOT_YET_RECRUITING | Limited Stage Small Cell Lung Cancer |
Tang-Du Hospital |
2025-05-20 | PHASE2 |
| NCT07548177 | RECRUITING | Alveolar Soft Part Sarcoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2026-04-02 | PHASE2 |
| NCT07538258 | NOT_YET_RECRUITING | Limited-stage Small Cell Lung Cancer (LS-SCLC) |
Yayi He |
2026-04-20 | PHASE2 |
| NCT07703228 | ACTIVE_NOT_RECRUITING | NSCLC (Advanced Non-small Cell Lung Cancer); NSCLC Stage IIIB~IV; Second-line Therapy; Metastases |
Nanfang Hospital, Southern Medical University |
2025-08-13 | PHASE2 |
| NCT07359053 | RECRUITING | Sarcoma |
Shanghai 6th People's Hospital |
2025-12-25 | PHASE2 |
| NCT07538271 | NOT_YET_RECRUITING | SCLC, Extensive Stage |
Yayi He |
2026-04-20 | PHASE2 |
| NCT07286240 | RECRUITING | Treatment of Recurrent Ovarian Cancer |
Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
2025-11-15 | PHASE2 |
| NCT07601178 | RECRUITING | TNBC, Triple Negative Breast Cancer |
Jiangsu Cancer Institute & Hospital |
2026-04-17 | PHASE2 |
| NCT06945705 | RECRUITING | NSCLC |
Henan Cancer Hospital |
2025-04-02 | PHASE2 |
| NCT07142421 | ACTIVE_NOT_RECRUITING | Esophageal Squamous Cell Carcinoma (ESCC) |
First Affiliated Hospital of Zhejiang University |
2025-08-06 | PHASE2 |
| NCT07443397 | RECRUITING | Whole-Brain Radiotherapy |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2025-08-29 | PHASE3 |
| NCT07501169 | NOT_YET_RECRUITING | Extensive-stage Small Cell Lung Cancer (ES-SCLC) |
Sichuan University |
2026-04-01 | PHASE2 |
| NCT07089199 | RECRUITING | NSCLC; Tislelizumab; Anlotinib; Nab-paclitaxel |
Qilu Hospital of Shandong University |
2025-07-25 | PHASE2 |
| NCT06506838 | RECRUITING | Soft Tissue Sarcoma; Doxorubicin; Radiotherapy |
Guangdong Provincial People's Hospital |
2024-08-10 | PHASE4 |
| NCT07635290 | ACTIVE_NOT_RECRUITING | Previously Treated, Advanced; Biliary Tract Cancers |
West China Hospital |
2026-06-03 | PHASE2 |
| NCT06977828 | NOT_YET_RECRUITING | NSCLC (Non-small Cell Lung Cancer); Neoadjuvant Immunotherapy; Adjuvant Immunotherapy |
The First Affiliated Hospital with Nanjing Medical University |
2025-07-20 | PHASE2 |
| NCT05830500 | RECRUITING | Medullary Thyroid Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2023-06-19 | PHASE4 |
| NCT06851247 | RECRUITING | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2025-01-03 | PHASE2 |
| NCT06429397 | NOT_YET_RECRUITING | Pheochromocytoma |
Sun Yat-sen University |
2025-05-01 | PHASE2 |
| NCT07022301 | NOT_YET_RECRUITING | Small Cell Lung Cancer Extensive Stage; Resistance to Immunotherapy |
First Affiliated Hospital of Wannan Medical College |
2025-07 | PHASE2 |
| NCT06931145 | NOT_YET_RECRUITING | Extensive-stage Small Cell Lung Cancer |
Peking Union Medical College Hospital |
2025-04-15 | PHASE4 |
| NCT07139470 | NOT_YET_RECRUITING | Triple Negative Breast Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2025-08-15 | PHASE1; PHASE2 |
| NCT06761417 | RECRUITING | Solid Tumors; Children; Adolescents |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2025-01-24 | PHASE2 |
| NCT06874933 | RECRUITING | HR+/HER2- Breast Cancer |
First Affiliated Hospital of Zhejiang University |
2025-05-04 | PHASE2 |
| NCT07438886 | NOT_YET_RECRUITING | Healthy Volunteer |
Advenchen Laboratories Nanjing Ltd. |
2026-03-02 | PHASE1 |
| NCT07320963 | NOT_YET_RECRUITING | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2026-03-31 | PHASE1; PHASE2 |
| NCT06761027 | RECRUITING | Locally Advanced Pancreatic Cancer; Metastatic Pancreatic Cancer |
Fujian Provincial Hospital |
2024-12-23 | PHASE1; PHASE2 |
| NCT07388875 | NOT_YET_RECRUITING | Extensive-Stage Small Cell Lung Cancer |
China Medical University, China |
2026-02-24 | PHASE2 |
| NCT06851169 | NOT_YET_RECRUITING | Non Small Cell Lung Cancer |
Tang-Du Hospital |
2025-04-01 | PHASE2 |
| NCT07489300 | NOT_YET_RECRUITING | Ovarian Cancer; Fallopian Tube Cancers; Primary Peritoneal Cancer |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2026-03-30 | PHASE2 |
| NCT07358520 | NOT_YET_RECRUITING | Proteinuria |
Fudan University |
2026-01-28 | PHASE4 |
| NCT07358676 | RECRUITING | Small Cell Lung Cancer (SCLC); SCLC, Extensive Stage |
Tianjin Medical University Cancer Institute and Hospital |
2026-02-01 | PHASE2 |
| NCT07510594 | NOT_YET_RECRUITING | Large-Cell Neuroendocrine Carcinoma of the Lung; Extrapulmonary Neuroendocrine Carcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2026-05-01 | PHASE2 |
| NCT06476093 | RECRUITING | Non-Small-Cell Lung Cancer; Brain Metastases |
The First People's Hospital of Lianyungang |
2024-07-01 | |
| NCT06739395 | RECRUITING | Solid Tumor; Precision Medicine |
Tianjin Medical University Second Hospital |
2024-11-01 | PHASE2 |
| NCT04959500 | ACTIVE_NOT_RECRUITING | Glioblastoma |
Sun Yat-sen University |
2021-07-21 | PHASE2 |
| NCT06331169 | RECRUITING | Breast Cancer |
Fudan University |
2024-07-31 | PHASE1 |
| NCT07025174 | RECRUITING | Bile Duct Carcinoma; Gall Bladder Cancer; Biliary Tract Cancer; Cholangiocarcinoma |
First Affiliated Hospital of Zhejiang University |
2025-06-01 | PHASE2 |
| NCT04136535 | RECRUITING | NSCLC Stage IV |
Fudan University |
2021-11-18 | PHASE2 |
| NCT06195228 | RECRUITING | Advanced Thyroid Cancer Patients Who Received Target Therapy |
Fudan University |
2020-01-01 | PHASE4 |
| NCT06699576 | NOT_YET_RECRUITING | Osteosarcoma; Soft Tissue Sarcoma (STS) |
Hansoh BioMedical R&D Company |
2024-12-20 | PHASE1 |
| NCT05926700 | RECRUITING | Soft Tissue Sarcoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2024-02-28 | PHASE2 |
| NCT06838910 | RECRUITING | Thymic Carcinoma; Thymoma |
The First Affiliated Hospital with Nanjing Medical University |
2025-03-31 | PHASE2 |
| NCT04344158 | ACTIVE_NOT_RECRUITING | Advanced Hepatocellular Carcinoma (HCC) |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-08-11 | PHASE3 |
| NCT06767813 | RECRUITING | Pancreatic Neoplasms |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
2024-03-19 | PHASE2 |
| NCT05252078 | RECRUITING | Esophageal Squamous Cell Carcinoma; Esophageal Neoplasms; Esophageal Diseases; Gastrointestinal Neoplasms; Gastrointestinal Diseases; Digestive System Neoplasms; Digestive System Diseases; Neoplasms by Site; Neoplasms by Histologic Type; Neoplasms, Squamous Cell; Carcinoma, Squamous Cell |
Jiangxi Provincial Cancer Hospital |
2022-06-02 | PHASE2 |
| NCT07746960 | ACTIVE_NOT_RECRUITING | Hepatocellular Carcinoma Non-Resectable |
Nanfang Hospital, Southern Medical University |
2025-01-01 | EARLY_PHASE1 |
| NCT06102928 | RECRUITING | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
Kunming Medical University |
2023-10-30 | |
| NCT05828953 | ACTIVE_NOT_RECRUITING | Interstitial Lung Diseases |
First Affiliated Hospital of Wenzhou Medical University |
2021-09-28 | PHASE2 |
| NCT06043973 | RECRUITING | Advanced Non-small Cell Lung Cancer |
Qianfoshan Hospital |
2023-09-01 | PHASE3 |
| NCT06469879 | NOT_YET_RECRUITING | Small Cell Lung Cancer Limited Stage |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2024-09 | PHASE3 |
| NCT05188859 | RECRUITING | Mesothelioma, Malignant; Mesothelioma, Malignant Pleural; Mesothelioma Malignant Advanced |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2024-09-01 | PHASE2 |
| NCT06634667 | NOT_YET_RECRUITING | Non-small Cell Lung Cancer |
Hunan Province Tumor Hospital |
2024-11-30 | PHASE2 |
| NCT06853769 | ACTIVE_NOT_RECRUITING | Colorectal Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2024-09-01 | EARLY_PHASE1 |
| NCT05742620 | NOT_YET_RECRUITING | Adjuvant Treatment |
Xijing Hospital |
2023-06-20 | |
| NCT06456138 | NOT_YET_RECRUITING | KRAS Mutation-Related Tumors; Advanced Lung Cancer; Refractory Tumor |
Shanghai Chest Hospital |
2024-07-01 | PHASE1; PHASE2 |
| NCT05214222 | RECRUITING | Advanced Esophageal Squamous Cell Carcinoma |
Nanfang Hospital, Southern Medical University |
2022-09-02 | PHASE2 |
| NCT06939452 | ACTIVE_NOT_RECRUITING | Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma |
Yongxu Jia |
2023-06-07 | PHASE2 |
| NCT06547476 | NOT_YET_RECRUITING | Breast Cancer |
Guangdong Provincial People's Hospital |
2024-09-01 | PHASE2 |
| NCT06352008 | RECRUITING | Non-Small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2024-07-01 | PHASE2 |
| NCT05913089 | RECRUITING | Non Small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2023-06-14 | PHASE2 |
| NCT06048315 | NOT_YET_RECRUITING | Lung Cancer; TKI Resistance; EGFR Sensitive Mutation; Anlotinib; Pianzumab |
Degan Lu |
2023-09 | PHASE3 |
| NCT06327698 | NOT_YET_RECRUITING | Melanoma |
Hunan Cancer Hospital |
2024-05-15 | PHASE2 |
| NCT06951841 | NOT_YET_RECRUITING | Small Cell Lung Cancer |
China Medical University, China |
2025-04-30 | PHASE4 |
| NCT06441344 | NOT_YET_RECRUITING | SCLC; Maintenance Treatment |
Taizhou Hospital |
2024-07-01 | PHASE3 |
| NCT06258642 | RECRUITING | Small Cell Lung Cancer Recurrent |
Fudan University |
2024-04-17 | |
| NCT06970145 | RECRUITING | Craniopharyngiomas |
Nanfang Hospital, Southern Medical University |
2025-04-25 | PHASE1; PHASE2 |
| NCT06897579 | TERMINATED | Extensive Stage Small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2025-04-07 | PHASE2 |
| NCT06886347 | RECRUITING | Metastatic Nasopharyngeal Carcinoma |
Chen Xiaozhong |
2023-07-07 | PHASE1 |
| NCT07376499 | NOT_YET_RECRUITING | Small Cell Lung Cancer |
China Medical University, China |
2026-01-25 | PHASE2 |
| NCT06901622 | ENROLLING_BY_INVITATION | Gallbladder Cancer and Extrahepatic Cholangiocarcinoma |
The First Affiliated Hospital of Zhengzhou University |
2024-11-08 | PHASE2 |
| NCT05736952 | WITHDRAWN | Platinum-resistant Ovarian Cancer |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2023-03-01 | PHASE2 |
| NCT05942508 | UNKNOWN | Limited Stage Small Cell Lung Cancer; Not Progressed After First-line Chemoradiotherapy |
Jinming Yu |
2023-05-30 | PHASE1 |
| NCT07037680 | RECRUITING | Locally Advanced Non-Small Cell Lung Cancer; Thoracic Radiotherapy; Safety |
JIANYANG WANG |
2024-01-01 | PHASE2 |
| NCT06182761 | NOT_YET_RECRUITING | NSCLC |
Shanghai Zhongshan Hospital |
2024-01 | PHASE2 |
| NCT06483672 | NOT_YET_RECRUITING | Adenocarcinoma of Lung Metastatic to Brain |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2024-07 | PHASE2 |
| NCT05685550 | ACTIVE_NOT_RECRUITING | Progression Free Survival(PFS) |
Tianjin Medical University Cancer Institute and Hospital |
2023-04-12 | PHASE2 |
| NCT06354530 | RECRUITING | Neoadjuvant Therapy; Esophageal Squamous Cell Carcinoma |
Army Medical Center of PLA |
2024-03-08 | PHASE2; PHASE3 |
| NCT06379087 | RECRUITING | Non-Small Cell Lung Cancer |
Ji Yongling |
2024-05-01 | PHASE2 |
| NCT06621095 | NOT_YET_RECRUITING | Pancreatic Cancer; First-line; Metastatic Pancreatic Cancer |
RenJi Hospital |
2024-10-30 | PHASE2 |
| NCT06211790 | RECRUITING | Kidney Cancer; Renal Cell Carcinoma; Renal Clear Cell Carcinoma |
Fudan University |
2024-01-16 | PHASE2 |
| NCT06355609 | RECRUITING | Non-small Cell Lung Cancer |
Hunan Province Tumor Hospital |
2024-07-01 | PHASE2 |
| NCT05301764 | COMPLETED | Soft Tissue Sarcoma |
Lyvgen Biopharma Holdings Limited |
2022-05-25 | PHASE1; PHASE2 |
| NCT06699498 | NOT_YET_RECRUITING | Head and Neck Squamous Cell Carcinoma; Neoadjuvant Therapy; PD-L1; Anlotinib |
The First Affiliated Hospital with Nanjing Medical University |
2024-12-03 | PHASE2 |
| NCT05550558 | NOT_YET_RECRUITING | Endometrial Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2022-11-01 | PHASE2 |
| NCT05817214 | RECRUITING | Cervical Cancer |
Zhongnan Hospital |
2023-02-16 | PHASE2 |
| NCT06585644 | NOT_YET_RECRUITING | Lung Cancer (NSCLC) |
Shanghai Pulmonary Hospital, Shanghai, China |
2024-10-01 | PHASE2 |
| NCT05844813 | ENROLLING_BY_INVITATION | Retroperitoneal Sarcoma |
Peking University International Hospital |
2022-11-01 | PHASE4 |
| NCT06348927 | RECRUITING | Non-Small Cell Lung Cancer |
Hunan Province Tumor Hospital |
2024-07-01 | PHASE2 |
| NCT04172805 | COMPLETED | Sarcoma,Soft Tissue |
Sun Yat-sen University |
2020-03-13 | PHASE2 |
| NCT06031480 | UNKNOWN | Hepatocellular Carcinoma |
Shanghai Zhongshan Hospital |
2023-10-31 | PHASE2 |
| NCT06678230 | UNKNOWN | Breast Cancer |
The First Hospital of Jilin University |
2024-11 | PHASE2 |
| NCT06086197 | RECRUITING | Diffuse Large B-cell Lymphoma Recurrent; Diffuse Large B Cell Lymphoma Refractory |
Zhejiang Cancer Hospital |
2023-10-01 | PHASE2 |
| NCT04772001 | UNKNOWN | Uterine Cervical Neoplasms; Chemoradiotherapy; Angiogenesis |
Zhongnan Hospital |
2021-03-12 | |
| NCT06188650 | RECRUITING | Non-Small Cell Lung Cancer |
Ningbo Medical Center Lihuili Hospital |
2023-12-09 | |
| NCT04807166 | ACTIVE_NOT_RECRUITING | Ovarian Neoplasms; Fallopian Tube Neoplasms; Neoplasms by Site; Genital Neoplasms, Female; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Carcinoma, Ovarian Epithelial; Ovarian Diseases; Genital Diseases, Female; Endocrine System Diseases; Carcinoma; Anlotinib; Angiogenesis; Antineoplastic Agents; Tyrosine Kinase Inhibitor |
Wenjun Cheng |
2021-08-24 | PHASE2 |
| NCT06660511 | RECRUITING | Ovarian Cancer Recurrent |
Second Xiangya Hospital of Central South University |
2024-10-15 | EARLY_PHASE1 |
| NCT06396585 | UNKNOWN | Immunotherapy Gastroesophageal Junction |
Fujian Cancer Hospital |
2024-08-01 | PHASE2 |
| NCT06605690 | NOT_YET_RECRUITING | Breast Cancer |
Liu Shu |
2024-10-31 | |
| NCT06222944 | UNKNOWN | Gastric Cancer; Adenocarcinoma of Esophagogastric Junction |
Peking University |
2024-02-25 | PHASE2 |
| NCT05990231 | UNKNOWN | Esophageal Squamous Cell Carcinoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2023-09-01 | PHASE2 |
| NCT06475287 | UNKNOWN | Hepatocellular Carcinoma |
Fudan University |
2024-07-20 | PHASE2 |
| NCT06033118 | UNKNOWN | Combined Hepatocellular Cholangiocarcinoma |
Sichuan University |
2023-10-01 | PHASE1; PHASE2 |
| NCT05807880 | ACTIVE_NOT_RECRUITING | Nasopharyngeal Neoplasms |
Sun Yat-sen University |
2023-09-01 | PHASE2 |
| NCT05375734 | COMPLETED | Pulmonary Pleomorphic Carcinoma; Immunotherapy; Tislelizumab |
Second Affiliated Hospital of Nanchang University |
2021-08-17 | PHASE2 |
| NCT06051851 | UNKNOWN | Pancreatic Adenocarcinoma Metastatic |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2023-07-01 | PHASE2 |
| NCT06438783 | TERMINATED | Osteosarcoma; Other Solid Tumors |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
2024-02-15 | PHASE1 |
| NCT06475755 | NOT_YET_RECRUITING | Non-Small Cell Lung Cancer; Anti Angiogenesis |
Tang-Du Hospital |
2024-06-30 | PHASE2 |
| NCT05975645 | TERMINATED | Advanced Hepatocellular Carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2023-08-15 | PHASE1 |
| NCT04523272 | ACTIVE_NOT_RECRUITING | Advanced Renal Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-08-25 | PHASE3 |
| NCT05218759 | UNKNOWN | Non-Small Cell Lung Cancer |
Shanghai Chest Hospital |
2022-02-21 | |
| NCT05229003 | UNKNOWN | Metastatic Colorectal Cancer |
Fudan University |
2022-03-09 | PHASE2 |
| NCT05842018 | UNKNOWN | Non Small Cell Lung Cancer Recurrent |
Tianjin Medical University Cancer Institute and Hospital |
2023-05-01 | PHASE2 |
| NCT06426797 | NOT_YET_RECRUITING | Locally Advanced Esophageal Squamous Cell Carcinoma |
Peking University People's Hospital |
2024-05 | PHASE2 |
| NCT05481775 | WITHDRAWN | Locally Advanced Non-small Cell Lung Cancer; Efficacy and Safety |
Sun Yat-sen University |
2022-04-01 | PHASE2 |
| NCT06586242 | RECRUITING | Esophageal Cancer |
Xijing Hospital |
2023-04-03 | PHASE2 |
| NCT05778149 | NOT_YET_RECRUITING | Aumolertinib; Anlotinib; TP53; NSCLC; EGFR Activating Mutation |
Tianjin Medical University Cancer Institute and Hospital |
2023-03-31 | PHASE2 |
| NCT04914390 | UNKNOWN | Triple-negative Breast Cancer |
Sichuan Provincial People's Hospital |
2023-09-15 | PHASE2 |
| NCT05193188 | UNKNOWN | Chondrosarcoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2023-02-06 | PHASE2 |
| NCT06010901 | UNKNOWN | Colorectal Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2024-01-13 | PHASE1 |
| NCT06221462 | NOT_YET_RECRUITING | Carcinoma, Non-Small-Cell Lung |
Ningbo No.2 Hospital |
2024-02-01 | PHASE2 |
| NCT05021328 | COMPLETED | NSCLC |
Hubei Cancer Hospital |
2021-10-01 | PHASE1 |
| NCT05001971 | COMPLETED | Small Cell Lung Cancer |
Hunan Cancer Hospital |
2021-01-30 | PHASE2 |
| NCT05271916 | RECRUITING | Non-Small Cell Lung Cancer (NSCLC) |
Shanghai Chest Hospital |
2022-10-13 | PHASE1; PHASE2 |
| NCT05193617 | ACTIVE_NOT_RECRUITING | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2022-01-20 | PHASE2 |
| NCT06015126 | UNKNOWN | Breast Cancer |
Yan Xue |
2022-10-05 | |
| NCT05539118 | NOT_YET_RECRUITING | Melanoma |
Xijing Hospital |
2022-09-30 | PHASE1; PHASE2 |
| NCT05218629 | UNKNOWN | Overall Survival |
Qingdao Central Hospital |
2022-01-01 | PHASE2 |
| NCT05028504 | UNKNOWN | Gynecological Cancer |
Sichuan Cancer Hospital and Research Institute |
2022-05-10 | PHASE2 |
| NCT05029102 | UNKNOWN | Gastric Cancer |
Zhejiang University |
2021-09-01 | PHASE2 |
| NCT05896059 | UNKNOWN | Extensive Stage Small Cell Lung Cancer |
Zhejiang Cancer Hospital |
2023-05-15 | PHASE2 |
| NCT03646968 | UNKNOWN | Non-Squamous Non Small Cell Lung Cancer |
Yongchang Zhang |
2018-08-01 | PHASE2 |
| NCT04854668 | ACTIVE_NOT_RECRUITING | Metastatic Colorectal Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2021-05-27 | PHASE3 |
| NCT06000033 | UNKNOWN | Breast Cancer |
Qilu Hospital of Shandong University |
2023-08-10 | PHASE2 |
| NCT06341530 | UNKNOWN | Non-small Cell Lung Cancer |
The First Affiliated Hospital of Zhengzhou University |
2024-01-31 | PHASE2 |
| NCT05681390 | UNKNOWN | Pancreatic Neoplasms |
First Affiliated Hospital Xi'an Jiaotong University |
2023-01-01 | PHASE2 |
| NCT05816499 | UNKNOWN | NSCLC Stage IV; NSCLC Stage IIIB; NSCLC Stage IIIC |
Shanghai Chest Hospital |
2023-02-16 | PHASE1; PHASE2 |
| NCT05659186 | UNKNOWN | Thyroid Cancer |
West China Hospital |
2022-12-30 | PHASE2 |
| NCT06062563 | UNKNOWN | Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma |
Peking Union Medical College Hospital |
2023-11-11 | |
| NCT04891900 | UNKNOWN | Gastric Cancer; Adenocarcinoma of Esophagogastric Junction |
Henan Cancer Hospital |
2021-05-10 | |
| NCT06482086 | RECRUITING | Locally Advanced Thyroid Gland Carcinoma |
West China Hospital |
2021-06-01 | PHASE2 |
| NCT06277674 | UNKNOWN | Non-small Cell Lung Cancer |
Guangzhou University of Traditional Chinese Medicine |
2023-11-02 | PHASE2 |
| NCT05715398 | UNKNOWN | Non-Small Cell Lung Cancer |
Shanghai Gopherwood Biotech Co., Ltd. |
2023-02 | PHASE1; PHASE2 |
| NCT05494060 | RECRUITING | Carcinoma; Gastrointestinal Diseases; Stomach Cancer; Gastroesophageal-junction Cancer; Digestive System Diseases; Gastric Cancer; Gastrointestinal Neoplasms |
The First Affiliated Hospital with Nanjing Medical University |
2022-03-16 | PHASE2 |
| NCT05220267 | ACTIVE_NOT_RECRUITING | Non Clear Cell Renal Carcinoma |
Sun Yat-sen University |
2022-02-28 | PHASE2 |
| NCT05007093 | ACTIVE_NOT_RECRUITING | DTC - Differentiated Thyroid Cancer |
Yansong Lin |
2020-12-01 | PHASE2 |
| NCT05996484 | UNKNOWN | Esophageal Carcinoma; Neoadjuvant Therapy |
Nanfang Hospital, Southern Medical University |
2023-09 | PHASE2 |
| NCT04278222 | UNKNOWN | Gastric Cancer; Immunotherapy; Anlotinib; Toripalimab |
Shanghai Changzheng Hospital |
2020-02-10 | PHASE2 |
| NCT05656222 | WITHDRAWN | Objective Response; Overall Survival |
Peking University People's Hospital |
2021-08-01 | |
| NCT05718167 | UNKNOWN | Advanced Squamous Non-Small Cell Lung Carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2023-02 | PHASE3 |
| NCT05145218 | UNKNOWN | Recurrent Platinum-resistant Ovarian Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2021-09-28 | PHASE3 |
| NCT02584478 | UNKNOWN | Endometrial Carcinoma; Ovarian Carcinoma; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma; Cervical Carcinoma |
Advenchen Laboratories, LLC |
2015-12 | PHASE3 |
| NCT05460195 | UNKNOWN | Non-small Cell Lung Cancer; Minimal Residual Disease; Immunotherapy; Anti-angiogenesis |
Shanghai Chest Hospital |
2022-01-01 | PHASE2 |
| NCT04691388 | COMPLETED | NSCLC |
Zhejiang Cancer Hospital |
2021-03-01 | PHASE2 |
| NCT05296577 | UNKNOWN | Breast Cancer |
Henan Cancer Hospital |
2022-03-22 | PHASE2 |
| NCT05558722 | ACTIVE_NOT_RECRUITING | Breast Cancer Stage II |
Xijing Hospital |
2022-12-05 | PHASE2 |
| NCT05862337 | RECRUITING | Hepatocellular Carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2023-05-10 | PHASE3 |
| NCT05490667 | UNKNOWN | Desmoid |
Henan Cancer Hospital |
2022-08-20 | |
| NCT04888546 | UNKNOWN | Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi |
Chinese Academy of Medical Sciences |
2021-04-30 | PHASE1; PHASE2 |
| NCT04660097 | COMPLETED | SCLC, Extensive Stage |
Henan Cancer Hospital |
2021-05-20 | PHASE2 |
| NCT04770688 | COMPLETED | Non-Small Cell Lung Cancer With EGFR Mutation; Locally Advanced Solid Tumor; Metastatic Cancer; Adenocarcinoma of Lung |
Shanghai Chest Hospital |
2020-11-19 | PHASE1; PHASE2 |
| NCT06611657 | ACTIVE_NOT_RECRUITING | Whole Brain Radiotherapy |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2021-08-20 | PHASE2 |
| NCT05772377 | UNKNOWN | To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2023-07-01 | PHASE2 |
| NCT04985851 | UNKNOWN | Extensive-Stage Small-Cell Lung Cancer |
Shanghai Chest Hospital |
2021-09-28 | |
| NCT05121350 | UNKNOWN | Soft Tissue Sarcoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2022-03 | PHASE3 |
| NCT04975451 | UNKNOWN | Breast Cancer |
Anqin Zhang |
2021-10-01 | PHASE2 |
| NCT05493995 | COMPLETED | Pancreatic Neoplasms |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2022-07-21 | PHASE2 |
| NCT05866510 | UNKNOWN | Esophageal Cancer |
Peking University |
2023-05-15 | PHASE2 |
| NCT05306847 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Peking Union Medical College Hospital |
2022-04-01 | PHASE2 |
| NCT06331169 | Not yet recruiting | Breast Cancer |
Fudan University |
2024-04-01 | Phase 1 |
| NCT04963088 | COMPLETED | Gastric Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2021-03-06 | PHASE1; PHASE2 |
| NCT05038813 | UNKNOWN | Esophageal Squamous Cell Carcinoma |
The First Affiliated Hospital of Zhengzhou University |
2022-03-14 | PHASE2 |
| NCT05137171 | UNKNOWN | Cervical Cancer |
The First Affiliated Hospital of Zhengzhou University |
2022-03-01 | PHASE2 |
| NCT05244993 | UNKNOWN | Breast Neoplasm Female |
Liaoning Cancer Hospital & Institute |
2022-07 | PHASE2 |
| NCT05385068 | UNKNOWN | Epithelial Ovarian Cancer |
Peking Union Medical College Hospital |
2022-06 | PHASE2 |
| NCT04803851 | UNKNOWN | Anlotinib; Anti-PD-1 Antibody; Advanced Pancreatic Cancer |
Peking Union Medical College Hospital |
2021-05-12 | PHASE1; PHASE2 |
| NCT05481645 | TERMINATED | Advanced Endometrial Cancer; Sarcoma of Uterus |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2022-08-26 | PHASE2 |
| NCT05800080 | UNKNOWN | Gastric Cancer |
Xijing Hospital |
2023-04 | |
| NCT05111366 | UNKNOWN | Hepatocellular Carcinoma; Adjuvant Therapy |
Xianhai Mao |
2022-01-06 | PHASE2 |
| NCT04197492 | UNKNOWN | Malignant Glioma |
Huashan Hospital |
2019-12-16 | PHASE2 |
| NCT04842526 | UNKNOWN | Refractory or Recurrent Neuroblastoma in Children |
Tianjin Medical University Cancer Institute and Hospital |
2021-04-12 | PHASE2 |
| NCT04762030 | UNKNOWN | Non Small Cell Lung Cancer |
Shanghai Pulmonary Hospital, Shanghai, China |
2021-02-08 | PHASE2 |
| NCT05400070 | ACTIVE_NOT_RECRUITING | Sintilimab; Lung Cancer; Anlotinib; Chemotherapy |
Tang-Du Hospital |
2021-03-01 | PHASE2 |
| NCT05883085 | UNKNOWN | Pheochromocytoma; Paraganglioma |
Peking Union Medical College Hospital |
2022-05-01 | PHASE2 |
| NCT05262335 | UNKNOWN | Gastrointestinal Tumors |
Ruijin Hospital |
2021-12-01 | PHASE2 |
| NCT04620473 | WITHDRAWN | Neoadjuvant Treatment; Rectal Cancer; Anlotinib |
Shanghai Minimally Invasive Surgery Center |
2023-11-01 | PHASE2 |
| NCT05124431 | UNKNOWN | Renal Cell Carcinoma |
Fudan University |
2021-12 | PHASE2 |
| NCT05346952 | UNKNOWN | Advanced Non-squamous Non-small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2022-01-25 | PHASE3 |
| NCT05068206 | UNKNOWN | Unresectable Metastatic Colorectal Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2021-10-08 | PHASE2 |
| NCT04895930 | UNKNOWN | Non-Small-Cell Lung Cancer |
Shanghai Chest Hospital |
2021-10-12 | PHASE2 |
| NCT05193604 | TERMINATED | Pancreatic Carcinoma |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
2022-03-24 | PHASE1 |
| NCT04574284 | COMPLETED | Advanced Endometrial Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-09-29 | PHASE2 |
| NCT04385550 | UNKNOWN | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-05-20 | PHASE3 |
| NCT04646330 | COMPLETED | NSCLC |
Akeso |
2020-11-18 | PHASE1; PHASE2 |
| NCT04860700 | COMPLETED | Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Pheochromocytoma, Metastatic; Paraganglioma, Malignant; Paraganglioma, Extra-Adrenal |
Peking Union Medical College Hospital |
2021-04-30 | PHASE2 |
| NCT05812430 | UNKNOWN | Advanced Biliary Tract Cancer |
The First Affiliated Hospital of Zhengzhou University |
2023-04-10 | PHASE2 |
| NCT04996758 | COMPLETED | Nasopharyngeal Carcinoma; Recurrent or Metastatic Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2021-10-30 | PHASE2 |
| NCT05087602 | UNKNOWN | Locally Advanced or Metastatic Acral Malignant Melanoma |
Qilu Hospital of Shandong University |
2021-11-01 | PHASE2 |
| NCT04271813 | COMPLETED | Colorectal Cancer; Immunotherapy; Anlotinib; Sintilimab; Chemo-free Therapy; First-line Treatment |
Shanghai Changzheng Hospital |
2020-06-01 | PHASE2 |
| NCT05600998 | UNKNOWN | Ovarian Clear Cell Carcinoma |
Peking University Third Hospital |
2022-10-30 | |
| NCT05485350 | UNKNOWN | Non-Small Cell Lung Cancer |
Peking University Third Hospital |
2022-09-12 | PHASE2 |
| NCT05133349 | UNKNOWN | Advanced or Metastatic Paraganglioma/ Pheochromocytoma |
Nanjing First Hospital, Nanjing Medical University |
2021-09-14 | PHASE2 |
| NCT04790409 | COMPLETED | Lung Cancer |
Zhejiang Cancer Hospital |
2019-08-01 | PHASE2 |
| NCT05030077 | UNKNOWN | Urothelial Carcinoma; Anlotinib; Urogenital Neoplasms; Cisplatin; Carboplatin; Gemcitabine; Antineoplastic Agents |
Tianjin Medical University Second Hospital |
2021-10-01 | PHASE2 |
| NCT04877821 | COMPLETED | Triple Negative Breast Cancer |
Guangdong Provincial People's Hospital |
2021-09-15 | PHASE2 |
| NCT05075512 | UNKNOWN | Breast Neoplasm Female |
Zhejiang Cancer Hospital |
2021-09-01 | PHASE2 |
| NCT06507891 | TERMINATED | Non Small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-07-06 | PHASE1; PHASE2 |
| NCT04797507 | UNKNOWN | SHR-1210; Anlotinib; Advanced Esophageal Squamous Cell Cancer |
Peking Union Medical College Hospital |
2021-03 | PHASE2 |
| NCT04952493 | UNKNOWN | Thyroid Cancer |
Peking Union Medical College Hospital |
2021-09-15 | PHASE2 |
| NCT04967079 | COMPLETED | Non Small Cell Lung Cancer |
Shanghai Chest Hospital |
2021-08-01 | PHASE1 |
| NCT05549973 | UNKNOWN | Multiple Myeloma |
Institute of Hematology & Blood Diseases Hospital, China |
2022-09 | PHASE1 |
| NCT04671303 | COMPLETED | Lung Cancer |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2021-01-01 | PHASE2 |
| NCT05385900 | UNKNOWN | Gastric Cancer |
Xijing Hospital |
2022-06-30 | |
| NCT03866980 | TERMINATED | Lung Cancer Non-small Cell Stage IV |
Akeso |
2018-11-27 | PHASE3 |
| NCT04936295 | UNKNOWN | Breast Cancer |
Sun Yat-sen University |
2021-06-16 | PHASE2 |
| NCT05460481 | UNKNOWN | Non Small Cell Lung Cancer |
Hunan Cancer Hospital |
2022-06-12 | PHASE2 |
| NCT05559242 | UNKNOWN | Liver Dysfunction |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2022-10 | PHASE1 |
| NCT05033587 | UNKNOWN | MGMT-Unmethylated Glioblastoma |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2021-09 | PHASE2 |
| NCT04055792 | COMPLETED | Extensive Disease Small Cell Lung Cancer |
Henan Cancer Hospital |
2019-09-11 | PHASE2 |
| NCT04846452 | UNKNOWN | Metastatic NSCLC; Recurrent NSCLC; Advanced Non-Small Cell Squamous Lung Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2021-06-01 | PHASE2 |
| NCT05121363 | UNKNOWN | Endometrial Carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2021-12 | PHASE2 |
| NCT05387109 | UNKNOWN | NSCLC |
Tang-Du Hospital |
2022-06-30 | PHASE4 |
| NCT05322499 | UNKNOWN | Stage IV Esophagus Squamous Cell Carcinoma |
Zhejiang Cancer Hospital |
2022-04-15 | PHASE2 |
| NCT04979585 | UNKNOWN | Melanoma |
Di Wu |
2021-07-15 | PHASE2 |
| NCT03950518 | UNKNOWN | HCC |
The First Affiliated Hospital of Zhengzhou University |
2019-04-10 | PHASE3 |
| NCT05344924 | UNKNOWN | Hepatocellular Carcinoma |
Zhongda Hospital |
2022-10-12 | PHASE2; PHASE3 |
| NCT05311579 | UNKNOWN | Ovarian Carcinoma; Survival Outcomes; Adverse Events; Niraparib; Anlotinib; CA125; Chemotherapy; Targeted Therapy; Recurrent Ovarian Cancer |
Lei Li |
2022-03-27 | PHASE2 |
| NCT04566952 | UNKNOWN | Ovarian Cancer; Ovarian and Fallopian Tube Cysts and Neoplasms; Neoplasms by Site; Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Carcinoma, Ovarian Epithelial; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Carcinoma; Anlotinib; PARP Inhibitors; BRCA1 Mutation; Angiogenesis; Antineoplastic Agents; BRCA2 Mutation |
Xiaoxiang Chen |
2020-10-28 | PHASE2 |
| NCT06015061 | Recruiting | Pheochromocytoma Metastatic|Ultrasonography|Paraganglioma Malignant|Pheochromocytoma Malignant |
Peking Union Medical College Hospital |
2023-03-01 | -- |
| NCT04846634 | NOT_YET_RECRUITING | Resectable Locally Advanced Non-small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2021-08 | PHASE2 |
| NCT04718701 | UNKNOWN | Pancreatic Neoplasm; Metastatic Pancreatic Cancer; Locally Advanced Pancreatic Adenocarcinoma |
The First Affiliated Hospital with Nanjing Medical University |
2021-04-01 | PHASE2 |
| NCT03940378 | UNKNOWN | ICC |
The First Affiliated Hospital of Zhengzhou University |
2019-02-01 | PHASE3 |
| NCT04213118 | UNKNOWN | Hepatocellular Carcinoma; TACE; Anlotinib |
First Affiliated Hospital Xi'an Jiaotong University |
2020-04-23 | PHASE2 |
| NCT05816499 | Recruiting | NSCLC Stage IV|NSCLC Stage IIIB|NSCLC Stage IIIC |
Shanghai Chest Hospital|The Affiliated Hospital of Qingdao University|Anhui Provincial Hospital|Zhejiang University |
2023-02-16 | Phase 1|Phase 2 |
| NCT04999800 | UNKNOWN | Head and Neck Squamous Cell Carcinoma |
Shi Yuankai |
2021-07-18 | PHASE2 |
| NCT05130515 | COMPLETED | Platinum-resistant Recurrent Clear Cell Ovarian Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2021-12-15 | PHASE2 |
| NCT04777162 | UNKNOWN | Gastric Cancer; Colo-rectal Cancer |
Peking University |
2021-03 | PHASE2 |
| NCT05602415 | UNKNOWN | Soft Tissue Sarcoma; High Risk of Recurrence; Anlotinib; Radiotherapy |
Ruijin Hospital |
2022-11 | PHASE2 |
| NCT04363255 | UNKNOWN | Small Cell Lung Carcinoma |
Taizhou Hospital |
2020-05-01 | PHASE2 |
| NCT04507035 | UNKNOWN | Head and Neck Cancer |
Sun Yat-sen University |
2020-09-01 | PHASE4 |
| NCT05453383 | UNKNOWN | Hepatocellular Cancer |
Shen Feng |
2022-07-08 | PHASE2 |
| NCT04967625 | UNKNOWN | Small Cell Lung Cancer Extensive Stage |
Zhejiang Cancer Hospital |
2021-07-26 | PHASE2 |
| NCT04765228 | UNKNOWN | Stage III Adult Soft Tissue Sarcoma |
Yong Chen |
2020-04-01 | PHASE2 |
| NCT04827004 | UNKNOWN | Diffuse Large B-cell Lymphoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2021-04 | PHASE2 |
| NCT04620837 | UNKNOWN | Small Cell Lung Carcinoma |
Chinese Academy of Medical Sciences |
2020-11-01 | PHASE2 |
| NCT05035914 | UNKNOWN | Advanced Colorectal Cancer |
Guangzhou University of Traditional Chinese Medicine |
2021-07-09 | PHASE1; PHASE2 |
| NCT04665609 | UNKNOWN | Hepatocellular Carcinoma; Thermal Ablation; Anlotinib; PDL-1 |
Chinese PLA General Hospital |
2021-03-05 | PHASE3 |
| NCT05013697 | UNKNOWN | Esophageal Neoplasms |
Henan Cancer Hospital |
2021-09 | PHASE2 |
| NCT05232552 | UNKNOWN | Nasopharyngeal Carcinoma |
Zhejiang Cancer Hospital |
2021-01-01 | PHASE2 |
| NCT04757779 | UNKNOWN | Relapsed Small Cell Lung Cancer; Anlotinib |
First People's Hospital of Hangzhou |
2019-12-30 | PHASE2 |
| NCT04659733 | UNKNOWN | Sarcoma |
Yizhuo Zhang |
2020-12-30 | PHASE1 |
| NCT04438902 | TERMINATED | Non Small Cell Lung Cancer |
First Affiliated Hospital of Zhejiang University |
2020-12-12 | PHASE2 |
| NCT04725214 | UNKNOWN | MGMT-Unmethylated Glioblastoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2021-01-15 | PHASE2 |
| NCT04325763 | UNKNOWN | Stage III Non-small-cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-05-27 | PHASE3 |
| NCT04964479 | UNKNOWN | Non Small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2021-08-06 | PHASE3 |
| NCT04291248 | UNKNOWN | MSI-H or dMMR Advanced Solid Tumors |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-03 | PHASE2 |
| NCT04157478 | UNKNOWN | Glioblastoma |
People's Hospital of Guangxi Zhuang Autonomous Region |
2020-01 | PHASE2 |
| NCT05311319 | UNKNOWN | Hepatocarcinoma |
Fudan University |
2022-01-11 | PHASE2 |
| NCT04234607 | UNKNOWN | Extensive Small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-01 | PHASE3 |
| NCT05027100 | UNKNOWN | Small Cell Lung Cancer (SCLC) |
Haibo Zhang |
2021-09-30 | |
| NCT04822805 | UNKNOWN | Recurrent High-grade Glioma |
First People's Hospital of Hangzhou |
2020-04-13 | PHASE2 |
| NCT05198531 | UNKNOWN | Recurrent / Metastatic Nasopharyngeal Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2022-01 | PHASE1; PHASE2 |
| NCT04924192 | TERMINATED | Advanced Lung Carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2021-08-18 | PHASE2 |
| NCT04547855 | UNKNOWN | Glioblastoma |
Yonggao Mou |
2020-09-11 | PHASE2 |
| NCT04157140 | UNKNOWN | Hepatocellular Carcinoma |
Jinglong Chen |
2019-11-28 | PHASE2 |
| NCT04544644 | UNKNOWN | Non-small Cell Lung Cancer |
Chinese PLA General Hospital |
2020-09 | PHASE2 |
| NCT04471480 | UNKNOWN | ESCC |
Dong Wang |
2020-09-01 | |
| NCT04720807 | UNKNOWN | Platinum-resistant Recurrent Ovarian Cancer |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2020-09-01 | PHASE2 |
| NCT03890068 | COMPLETED | Soft Tissue Sarcoma |
Sun Yat-sen University |
2019-04-11 | PHASE2 |
| NCT04119674 | COMPLETED | Glioblastoma |
Zhejiang Cancer Hospital |
2019-03-19 | PHASE1; PHASE2 |
| NCT04970914 | UNKNOWN | Colorectal Cancer |
Peking Union Medical College Hospital |
2021-11-05 | PHASE2 |
| NCT03946943 | UNKNOWN | Soft Tissue Sarcomas; Undifferentiated Pleomorphic Sarcoma |
Di Wu |
2019-07-19 | PHASE2 |
| NCT04452370 | UNKNOWN | Triple Negative Breast Cancer |
Chinese Academy of Medical Sciences |
2020-09-23 | PHASE2 |
| NCT04405505 | UNKNOWN | Triple Negative Breast Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-06-01 | PHASE3 |
| NCT04731038 | UNKNOWN | Advanced Cervical Cancer |
Ruijin Hospital |
2021-08-01 | PHASE1 |
| NCT04453423 | UNKNOWN | Non-squamous Non-small-cell Lung Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2020-07-01 | PHASE2 |
| NCT04668508 | UNKNOWN | Malignant Brain Stem Tumor; Glioma |
Zhejiang Cancer Hospital |
2020-11-24 | PHASE2 |
| NCT03945799 | TERMINATED | Hepatocellular Carcinoma |
Zhejiang University |
2019-04-22 | PHASE1; PHASE2 |
| NCT04736810 | COMPLETED | Nasopharyngeal Carcinoma |
Akeso |
2021-02-25 | PHASE2 |
| NCT04731909 | UNKNOWN | SCLC, Extensive Stage; Lung Cancer; Small Cell Lung Cancer |
Third Military Medical University |
2018-10-01 | |
| NCT03951571 | COMPLETED | Soft Tissue Sarcoma Adult; High Grade Sarcoma |
Fudan University |
2019-05-13 | PHASE2 |
| NCT04172571 | COMPLETED | Hepatocellular Carcinoma |
Akeso |
2018-11-22 | PHASE2 |
| NCT04080843 | COMPLETED | Colorectal Cancer; RAS and BRAF Wild-type; Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases |
Zhejiang University |
2019-11-15 | PHASE2 |
| NCT04933175 | UNKNOWN | Extensive Stage Small Cell Lung Cancer |
Liu Zhenhua |
2021-06 | PHASE2 |
| NCT04624711 | UNKNOWN | HER2-negative Breast Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2021-03-01 | PHASE2 |
| NCT04978753 | UNKNOWN | Non-small Cell Lung Cancer; Brain Metastases |
Li-kun Chen |
2021-05-01 | PHASE2 |
| NCT04358562 | UNKNOWN | Non-small Cell Lung Cancer; EGFR Gene Mutation |
Second Affiliated Hospital of Nanchang University |
2020-05-01 | PHASE2 |
| NCT05883085 | Recruiting | Pheochromocytoma|Paraganglioma |
Peking Union Medical College Hospital |
2022-05-01 | Phase 2 |
| NCT05301764 | Recruiting | Soft Tissue Sarcoma |
Lyvgen Biopharma Holdings Limited |
2022-05-25 | Phase 1|Phase 2 |
| NCT05206656 | COMPLETED | Metastatic Breast Cancer |
Hunan Cancer Hospital |
2020-10-09 | PHASE2 |
| NCT04797806 | UNKNOWN | Non Small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2021-03-12 | PHASE3 |
| NCT06015035 | COMPLETED | Sintilimab and Anlotinib in Combination With Chemotherapy |
Tang-Du Hospital |
2021-04-01 | PHASE2 |
| NCT04316351 | UNKNOWN | IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy |
Guangzhou Institute of Respiratory Disease |
2020-04-01 | PHASE2 |
| NCT04507906 | COMPLETED | NSCLC Stage IV; Checkpoint Inhibitor |
Shanghai Chest Hospital |
2020-11-02 | PHASE1; PHASE2 |
| NCT04809142 | UNKNOWN | Advanced Biliary Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2021-02-04 | PHASE3 |
| NCT04063683 | UNKNOWN | Esophageal Squamous Cell Carcinoma |
Henan Cancer Hospital |
2019-10-07 | PHASE2 |
| NCT04813406 | UNKNOWN | Esophageal Squamous Cell Carcinoma |
Henan Provincial People's Hospital |
2021-03 | |
| NCT04236362 | UNKNOWN | Gynecological Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-02-27 | PHASE1; PHASE2 |
| NCT04376073 | UNKNOWN | Platinum-resistant Ovarian Cancer |
Jihong Liu |
2020-05-22 | PHASE2 |
| NCT03936452 | COMPLETED | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type; Early Stage; Anlotinib; Peg-aspargase; Sintilimab; Phase Two; Open; Radiotherapy |
Sun Yat-sen University |
2019-04-28 | PHASE2 |
| NCT04147728 | UNKNOWN | Stereotactic Body Radiation Therapy |
Peking University Third Hospital |
2019-12-24 | PHASE2 |
| NCT03387904 | UNKNOWN | Esophageal Squamous Cell Carcinoma |
The First Affiliated Hospital of Zhengzhou University |
2019-01-13 | PHASE2 |
| NCT04958993 | TERMINATED | Non-small Cell Lung Cancer |
Shandong Cancer Hospital and Institute |
2020-11-12 | PHASE1; PHASE2 |
| NCT04164745 | UNKNOWN | NSCLC |
Peking Union Medical College Hospital |
2019-11-16 | PHASE2 |
| NCT03743129 | COMPLETED | Non-Small Cell Lung Cancer Stage III |
Anhui Shi, MD |
2019-04-12 | PHASE2 |
| NCT04764084 | UNKNOWN | HER2-negative Breast Cancer; Gastric Adenocarcinoma; Cholangiocarcinoma; Pancreatic Cancer |
Peking University Cancer Hospital & Institute |
2021-04-01 | PHASE1 |
| NCT03755869 | UNKNOWN | Non-squamous NSCLC |
First Affiliated Hospital Xi'an Jiaotong University |
2018-11-29 | PHASE4 |
| NCT04042597 | UNKNOWN | Effect of Drugs; Quality of Life; Chordoma; Advanced Cancer |
Peking University People's Hospital |
2019-07-18 | PHASE2 |
| NCT04619537 | UNKNOWN | Non Small Cell Lung Cancer |
Shandong Cancer Hospital and Institute |
2020-10-08 | PHASE2 |
| NCT04619563 | UNKNOWN | Non Small Cell Lung Cancer |
Shandong Cancer Hospital and Institute |
2020-11-04 | PHASE2 |
| NCT04684017 | UNKNOWN | SCLC; Anlotinib |
Shanghai Chest Hospital |
2019-05-01 | PHASE2 |
| NCT03639467 | UNKNOWN | Recurrent Nasopharyngeal Carcinoma; Metastatic Nasopharyngeal Carcinoma |
Chinese Academy of Medical Sciences |
2018-09-18 | PHASE1; PHASE2 |
| NCT04181372 | UNKNOWN | Stage III Non-small-cell Lung Cancer |
The First Affiliated Hospital of Guangzhou Medical University |
2019-12 | PHASE2 |
| NCT04073550 | UNKNOWN | Small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-10-31 | PHASE3 |
| NCT04073537 | UNKNOWN | Squamous Non-small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-10-31 | PHASE3 |
| NCT04211896 | UNKNOWN | Non Small Cell Lung Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2020-01-01 | PHASE2 |
| NCT04882033 | UNKNOWN | Small Cell Lung Cancer Limited Stage |
Tianjin Medical University Cancer Institute and Hospital |
2021-05-07 | PHASE1 |
| NCT04007835 | UNKNOWN | NSCLC |
Guangdong Association of Clinical Trials |
2019-07 | |
| NCT04439890 | UNKNOWN | Advanced Non-squamous Cell Non-small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-08-08 | PHASE3 |
| NCT03720873 | UNKNOWN | EGFR Gene Mutation |
Fujian Cancer Hospital |
2018-10 | PHASE2 |
| NCT04066543 | UNKNOWN | Carcinoma, Hepatocellular |
Zhejiang Cancer Hospital |
2019-08-30 | PHASE2 |
| NCT04182698 | UNKNOWN | Patients With Non-small Cell Lung Cancer |
Second Affiliated Hospital of Xi'an Jiaotong University |
2019-11-22 | PHASE1; PHASE2 |
| NCT03618238 | COMPLETED | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2018-07-25 | PHASE2 |
| NCT03924882 | UNKNOWN | Ovarian Cancer |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2019-04-25 | PHASE2 |
| NCT04124731 | UNKNOWN | Carcinoma; Non-small Cell Lung Cancer |
Shanghai Chest Hospital |
2019-10 | PHASE2 |
| NCT03880695 | UNKNOWN | Sarcoma |
Peking University People's Hospital |
2019-03 | PHASE2 |
| NCT03706287 | UNKNOWN | Lung Cancer Metastatic |
Sichuan Cancer Hospital and Research Institute |
2018-12-06 | PHASE1; PHASE2 |
| NCT04192682 | UNKNOWN | Small Cell Lung Cancer |
Changzhou Cancer Hospital of Soochow University |
2019-05-08 | PHASE2; PHASE3 |
| NCT03906058 | COMPLETED | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2019-04-29 | PHASE2 |
| NCT04309136 | UNKNOWN | Thyroid Cancer |
Fudan University |
2019-06-01 | PHASE2 |
| NCT04503967 | UNKNOWN | Gastric Adenocarcinoma; Esophageal Squamous Cell Carcinoma |
Shanghai Zhongshan Hospital |
2020-08-01 | PHASE2 |
| NCT04314297 | UNKNOWN | Anlotinib; Durvalumab; Small Cell Lung Cancer |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2020-04 | PHASE2 |
| NCT04313660 | UNKNOWN | NSCLC; Anlotinib; PD-1/L1 Inhibitor |
Xiaorong Dong |
2020-04 | PHASE2 |
| NCT04080154 | UNKNOWN | Hepatocellular Carcinoma |
Shanghai Zhongshan Hospital |
2019-09-24 | PHASE2 |
| NCT04223583 | COMPLETED | Soft Tissue Sarcomas |
Henan Cancer Hospital |
2019-06-26 | PHASE4 |
| NCT04273815 | UNKNOWN | Non-small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-07-06 | PHASE1; PHASE2 |
| NCT03825705 | UNKNOWN | Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-04-23 | PHASE1; PHASE2 |
| NCT03736837 | COMPLETED | Non Small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2018-12-01 | PHASE2 |
| NCT04300959 | UNKNOWN | Biliary Tract Cancer |
Zhejiang Cancer Hospital |
2020-01-01 | PHASE2 |
| NCT04207463 | UNKNOWN | Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-06-03 | PHASE2 |
| NCT04203719 | UNKNOWN | Advanced Head, Neck and Chest Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-05-09 | PHASE2 |
| NCT03998085 | UNKNOWN | Non-Small Cell Lung Cancer |
The First Hospital of Jilin University |
2019-03-05 | |
| NCT03910127 | UNKNOWN | Non-small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-06-11 | PHASE1 |
| NCT04157491 | UNKNOWN | Endometrial Cancer |
Sun Yat-sen University |
2019-10-18 | PHASE1; PHASE2 |
| NCT03996408 | UNKNOWN | Advanced Cholangiocarcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-06-24 | PHASE1; PHASE2 |
| NCT03769805 | UNKNOWN | Nonsmall Cell Lung Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2019-06-15 | |
| NCT04675697 | UNKNOWN | Extensive-stage Small-cell Lung Cancer |
Xiangya Hospital of Central South University |
2019-01-24 | PHASE2 |
| NCT04611711 | UNKNOWN | Patients With Digestive System Tumors Resistant to PD-1 Inhibitors |
Peking University |
2020-11-01 | PHASE1; PHASE2 |
| NCT03792542 | UNKNOWN | Soft Tissue Sarcoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2019-01 | PHASE2 |
| NCT04028778 | UNKNOWN | Lung Cancer, Nonsmall Cell |
Sun Yat-sen University |
2019-04-10 | PHASE3 |
| NCT03781869 | UNKNOWN | Extensive-stage Small Cell Lung Cancer |
Third Military Medical University |
2018-12 | PHASE2 |
| NCT03750916 | UNKNOWN | Non Small Cell Lung Cancer |
Qilu Hospital of Shandong University |
2018-11-30 | PHASE2 |
| NCT03700359 | UNKNOWN | Small Cell Lung Carcinoma |
The First Affiliated Hospital of Guangzhou Medical University |
2019-03-01 | PHASE2 |
| NCT03983928 | UNKNOWN | Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-06-03 | PHASE1; PHASE2 |
| NCT03735264 | UNKNOWN | Non Small Cell Lung Cancer |
The Affiliated Hospital of Qingdao University |
2018-11-15 | PHASE2 |
| NCT03790228 | UNKNOWN | Non-squamous Cell Non-Small Cell Lung Cancer |
Henan Cancer Hospital |
2019-03-22 | PHASE1 |
| NCT04670107 | COMPLETED | NSCLC; Angiogenesis; Immunotherapy |
The Affiliated Hospital of Qingdao University |
2018-06-01 | PHASE1; PHASE2 |
| NCT04232397 | TERMINATED | Chronic Graft-versus-host-disease |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2020-04-10 | PHASE2 |
| NCT04111913 | UNKNOWN | Unresectable Stage III Non-small Cell Lung Cancer |
Nanfang Hospital, Southern Medical University |
2019-10-01 | PHASE2 |
| NCT03589950 | UNKNOWN | Lung Neoplasms; Docetaxel; Pemetrexed; S-1; Anlotinib |
The First People's Hospital of Lianyungang |
2018-08-01 | PHASE2 |
| NCT03601975 | UNKNOWN | Nasopharyngeal Carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2018-08-27 | PHASE3 |
| NCT04004975 | UNKNOWN | Recurrent Glioblastoma |
Shandong Cancer Hospital and Institute |
2019-06-25 | PHASE1; PHASE2 |
| NCT03929965 | UNKNOWN | Advanced Solid Tumor |
Shanghai Changzheng Hospital |
2019-07-01 | |
| NCT03624309 | UNKNOWN | Non-small Cell Lung Cancer |
Hunan Cancer Hospital |
2018-10-15 | PHASE2 |
| NCT03897283 | UNKNOWN | Advanced Solid Tumors |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-06-20 | PHASE1 |
| NCT03855358 | UNKNOWN | Triple Negative Breast Cancer (TNBC) |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-05-09 | PHASE1 |
| NCT03823118 | COMPLETED | Small Cell Lung Cancer Recurrent |
Taizhou Hospital |
2019-03-01 | PHASE2 |
| NCT03975036 | UNKNOWN | Advanced Solid Tumor |
Henan Cancer Hospital |
2019-04-08 | PHASE2; PHASE3 |
| NCT03732846 | UNKNOWN | Recurrent Small Cell Lung Cancer |
Peking University Cancer Hospital & Institute |
2018-11-01 | PHASE2 |
| NCT03890055 | UNKNOWN | Small Cell Lung Cancer |
Chifeng Municipal Hospital |
2019-04-01 | PHASE4 |
| NCT03991975 | UNKNOWN | Advanced Acral Malignant Melanoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-06-11 | PHASE1; PHASE2 |
| NCT03416517 | UNKNOWN | Ewing's Tumor Metastatic |
Peking University People's Hospital |
2018-01-22 | PHASE1; PHASE2 |
| NCT04029350 | UNKNOWN | Non Small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2019-07-31 | PHASE2 |
| NCT04002284 | COMPLETED | Breast Neoplasm; Antineoplastic Agents; Anlotinib |
Peng Yuan |
2018-07-12 | PHASE2 |
| NCT03780283 | UNKNOWN | Carcinoma; Lung Neoplasm; Small Cell Lung Cancer |
First Hospital of Shijiazhuang City |
2019-01-01 | PHASE2 |
| NCT03527888 | UNKNOWN | Neoplasm of Bone |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2018-01-31 | PHASE2 |
| NCT03778138 | UNKNOWN | Non-squamous Cell Non-Small Cell Lung Cancer |
Henan Provincial People's Hospital |
2019-01-01 | PHASE2 |
| NCT03815474 | UNKNOWN | Sarcoma, Soft Tissue |
Liaoning Cancer Hospital & Institute |
2019-05-20 | PHASE2 |
| NCT03765775 | UNKNOWN | Carcinoma; Non-small Cell Lung Cancer; Lung Neoplasm |
First Hospital of Shijiazhuang City |
2018-11-20 | PHASE2 |
| NCT03591666 | UNKNOWN | Head and Neck Carcinoma; Adenocarcinoma; Recurrent Disease; Distantly Metastatic Malignant Neoplasm |
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University |
2018-07-15 | PHASE2 |
| NCT03628521 | UNKNOWN | Lung Cancer; Advanced Stage |
Shanghai Chest Hospital |
2018-07-20 | PHASE1 |
| NCT03766776 | UNKNOWN | Cancer of Liver |
The First Affiliated Hospital with Nanjing Medical University |
2018-12-31 | |
| NCT04052152 | UNKNOWN | Advanced Hepatocellular Carcinoma |
The First Affiliated Hospital with Nanjing Medical University |
2019-06-10 | PHASE2 |
| NCT03766490 | UNKNOWN | Non-Small-Cell Lung |
The First Affiliated Hospital of Soochow University |
2019-03-30 | |
| NCT03841136 | UNKNOWN | Extensive-stage Small Cell Lung Cancer |
Fudan University |
2019-04-01 | PHASE2 |
| NCT03799601 | UNKNOWN | NSCLC |
Tongji Hospital |
2019-03-01 | PHASE4 |
| NCT02586337 | UNKNOWN | Differentiated Thyroid Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2015-07 | PHASE2; PHASE3 |
| NCT03778853 | UNKNOWN | Advanced Non-squamous NSCLC |
LanZhou University |
2019-01 | PHASE4 |
| NCT03768037 | UNKNOWN | Advanced Non-squamous NSCLC |
Guangdong Association of Clinical Trials |
2018-11-26 | PHASE4 |
| NCT03545711 | UNKNOWN | Colo-rectal Cancer |
Chinese Academy of Medical Sciences |
2018-05-26 | PHASE1; PHASE2 |
| NCT03732001 | UNKNOWN | Non-small Cell Lung Cancer |
China Medical University, China |
2018-11-08 | PHASE2 |
| NCT04012619 | COMPLETED | Non-squamous Non-small-cell Lung Cancer; Anlotinib |
Sichuan University |
2019-04-30 | PHASE1 |
| NCT03726736 | UNKNOWN | Non-small Cell Lung Cancer |
Yong Fang |
2018-12-21 | PHASE1; PHASE2 |
| NCT03672136 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Shandong Cancer Hospital and Institute |
2018-11-01 | PHASE2 |
| NCT03728374 | UNKNOWN | Non-Small-Cell Lung Cancer |
First Affiliated Hospital of Wenzhou Medical University |
2018-11-01 | PHASE2 |
| NCT03703596 | UNKNOWN | Lung Cancer; Lung Cancer Metastatic |
Sichuan Cancer Hospital and Research Institute |
2018-10-16 | PHASE2 |
| NCT04106024 | UNKNOWN | Gastrointestinal Stromal Tumors |
Cttq |
2018-10-23 | PHASE2 |
| NCT03654027 | UNKNOWN | Non-small Cell Lung Cancer |
First Affiliated Hospital of Guangxi Medical University |
2018-10-01 | PHASE2 |
| NCT03671538 | UNKNOWN | Non-squamous Non-small Cell Lung Cancer |
Lingyu Luo |
2018-10-01 | |
| NCT03457844 | UNKNOWN | Gastroenteropancreatic Neuroendocrine Tumor G3 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2018-01-30 | PHASE2 |
| NCT03636685 | UNKNOWN | NSCLC; Adenocarcinoma; Squamous Cell Carcinoma |
Chinese Academy of Medical Sciences |
2018-08-15 | PHASE1; PHASE2 |
| NCT05089643 | UNKNOWN | Metastatic Triple-Negative Breast Cancer |
Chinese Academy of Medical Sciences |
2019-04-11 | PHASE2 |
| NCT04947371 | WITHDRAWN | Hepatocellular Carcinoma |
Shanghai Zhongshan Hospital |
2018-12-15 | PHASE2 |
| NCT03602027 | UNKNOWN | Non-squamous Non-small Cell Lung Cancer |
Second Affiliated Hospital of Nanchang University |
2018-08-01 | |
| NCT02586350 | COMPLETED | Medullary Thyroid Carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2015-07 | PHASE2; PHASE3 |
| NCT03566576 | UNKNOWN | Non-squamous Non-small Cell Lung Cancer |
Fujian Cancer Hospital |
2018-07-01 | |
| NCT02825563 | COMPLETED | Advanced Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2016-06 | PHASE1 |
| NCT02649361 | COMPLETED | Esophageal Squamous Cell Carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2016-01 | PHASE2 |
| NCT03059797 | COMPLETED | Small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2017-03-27 | PHASE2 |
| NCT02461407 | UNKNOWN | Gastric Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2015-06 | PHASE2; PHASE3 |
| NCT02072044 | UNKNOWN | Renal Cell Carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2013-12 | PHASE2 |
| NCT02809534 | UNKNOWN | Hepatocellular Carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2016-09 | PHASE2 |
| NCT02752516 | UNKNOWN | Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2016-04-27 | PHASE1 |
| NCT02449343 | UNKNOWN | Soft Tissue Sarcoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2015-05-12 | PHASE2; PHASE3 |
| NCT02029209 | UNKNOWN | Non-small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2013-12 | PHASE2; PHASE3 |
| NCT02558348 | TERMINATED | Endometrial Cancer; Ovarian Cancer; Cervical Cancer |
Advenchen Laboratories, LLC |
2015-11 | PHASE1; PHASE2 |
| NCT02388919 | COMPLETED | Non-small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2015-02-26 | PHASE2; PHASE3 |
| NCT02622932 | COMPLETED | Advanced Solid Tumors |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2015-12-02 | PHASE1 |
| NCT01874873 | COMPLETED | Tumor |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2013-04 | PHASE2 |
| NCT02072031 | UNKNOWN | Anlotinib; RCC |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2013-12 | PHASE2 |
| NCT02332499 | COMPLETED | Metastatic Colorectal Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2014-12 | PHASE2; PHASE3 |
| NCT01833923 | COMPLETED | Advanced Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2011-05 | PHASE1 |
| NCT01878448 | COMPLETED | Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2013-04 | PHASE2 |
| NCT01924195 | COMPLETED | Non-small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2013-08 | PHASE2 |
| NCT04216082 | COMPLETED | Advanced Malignancy |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2013-08-01 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-04-22)
Check the
Anlotinib (AL3818) Dihydrochloride
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Anlotinib (AL3818) Dihydrochloride Solubility in DMSO
- Anlotinib (AL3818) Dihydrochloride Stock Solution
- Anlotinib (AL3818) Dihydrochloride Storage
- Anlotinib (AL3818) Dihydrochloride Stability
- Anlotinib (AL3818) Dihydrochloride Molecular Weight
- Anlotinib (AL3818) Dihydrochloride SMILES
- Anlotinib (AL3818) Dihydrochloride CAS Number
- Anlotinib (AL3818) Dihydrochloride Chemical Structure (2D and 3D)
- Anlotinib (AL3818) Dihydrochloride SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.